MPT — Stock Film
STOCK FILMSCENE 1/11MPT · $4.80
Stock Expert AI presents
MPT
Medical Properties Trust, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Medical Properties Trust, Inc. A quick introduction.

On the stock market since 2005, it operates in the world of real estate. It has 121 employees. Now — the numbers.

on the stock market since 2005
121 employees
$2.9B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.3.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 11% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$1.5B
2021
$1.5B
2022
$871.8M
2023
$995.5M
2024
$972M
2025
In the vault right now:
$0
DEBT: $9.8B
At this pace, that money lasts about 2 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
55
average

Profit indicators sit around the sector average.

FINANCIAL STRENGTH
48
weak

Clearly below the class average.

VALUATION
59
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
30
very weak

Clearly below the class average.

PRICE MOMENTUM
28
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Few are betting against it10/10
WEAK SPOTS
Growth has stalled2/10
Costs eat into the margin4/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 80% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Analysts’ target sits above today’s price

The average analyst price target is $8.0067% above today’s price.

2
THE BRIGHT SIDE · 2/2
Pays a steady dividend

It pays out $0.35 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/2
The losses continue

A loss of $277.0M against $972.0M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 2 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, MPT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: MPT has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (59/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film